|
|
 |
 |
 |
ONCOMETHYLOME SCIENCES TO PARTICIPATE IN AN INTERNATIONAL CLINICAL TRIAL TO OPTI |
 |
|
 |
|
Posted by wvcrieki on Friday, April 28 @ 16:34:49 CEST (2392 reads)
(Read More... | 2637 bytes more | Score: 3.90)
|
|
 |
|
 |
|
 Anonymous writes "OncoMethylome Sciences to Provide MGMT Gene Methylation Testing in a Phase III Clinical Trial for Patients with Brain Tumors, Conducted Jointly by the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer.
DURHAM, NC (USA) and LIEGE (BELGIUM) ― April 5, 2006 ― OncoMethylome Sciences announced today that it will perform MGMT gene methylation testing for a multi-center clinical trial for patients with brain tumors conducted jointly by the U.S.-based Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). With patient enrollment underway, the trial was designed to determine whether increasing the intensity of temozolomide drug treatment regimen for patients with glioblastoma multiforme tumors improves clinical outcomes over standard-dose temozolomide. This phase III trial brings together a valuable network of international medical centers and universities and is the first such collaborative study between RTOG and EORTC organizations."
|
|
|
|
|
|
|
|
|
|
BiotechIndustryStocks.com, Biotechnology Investor Portal, Adds To Online Content |
|
|
|
|
|
|
|
|
|
|
Anonymous writes "BiotechIndustryStocks.com, Biotechnology Investor Portal, Adds To Online Content with New Service: News and Article Submission for Biotech Companies
POINT ROBERTS, Wash., Delta, B.C. – April 27, 2006 – www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector, announces a new service for public and private companies to submit press releases to online visitors following the industry. In addition, BiotechIndustryStocks.com has added a new feature for freelance journalists and industry experts to contribute articles. The new content will build upon the highly visited portal articles, written by in-house writers and well known financial journalist Michael Brush. Additionally the site features audio interviews, stock directories, audio conferences, blogs, RSS feeds and links.
BiotechIndustryStocks.com Content Submission Pages:
To submit Biotech news to be read by investors and industry following the biotech sector: http://www.biotechindustrystocks.com/NewsUploader/
To submit Biotech articles to be read by investors and industry following the biotechnology sector: http://www.biotechindustrystocks.com/NewsUploader/Submit_Article/
About BiotechIndustryStocks.com
www.BiotechIndustryStocks.com, a portal within the InvestorIdeas.com ™ content umbrella, is an investor and industry news portal for the Biotech and Pharma sector. The website does not make recommendations, but offers a unique free information portal to research news, exclusive articles, interviews, investor conferences and a growing list of participating public companies in the sector.
Additionally the site features a growing directory of Biotech Stocks: http://www.investorideas.com/Research/Biotech,PharmaStocks.asp
Additional Investor Content within the InvestorIdeas.com ™ content umbrella:
Investor Incite Newsletter
InvestorIdeas.com™ free "Investor Incite" newsletter consists of company and industry updates, investment research and developing trends in key areas such as Homeland Security, Renewable Energy, Biotech, Oil and Gas and more. To sign up, click here: www.InvestorIdeas.com/Resources/Newsletter.asp
The "Insiders Corner": Insiders Corner by Michael Brush offers analysis of significant insider purchases at small-cap and micro-cap stocks
http://www.investorideas.com/insiderscorner/
Investor Online Audio Conferences: Online audio presentations with public companies and industry experts
http://www.investorideas.com/forums/
InvestorIdeas.com™ Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. These sites are currently compensated for by "featured companies."
For more information contact:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Ann Marie Fleming: 866-725-2554 - afleming@investorideas.com
"
|
|
|
|
|
|
|
|
|
|
Agency Takes a Preliminary Step to Revoke a Genentech Patent |
|
|
|
|
Posted by mlambrecht on Wednesday, October 05 @ 13:05:00 CEST (2245 reads)
(Read More... | 343 bytes more | Score: 5)
|
|
|
|
|
|
| In a preliminary ruling, patent examiners said Genentech's claims represented "double-patenting," meaning the new patent, awarded in 2001, covered basically the same invention as an earlier Genentech patent that was set to expire next March.
|
|
|
|
|
|
|
|
|
|
Crawford resigns as FDA Commissioner |
|
|
|
|
Posted by mlambrecht on Sunday, October 02 @ 22:56:45 CEST (2206 reads)
(Read More... | 723 bytes more | Score: 5)
|
|
|
|
|
|
| The US Food and Drug Administration (FDA) has found itself once again without a permanent Commissioner after the current incumbent - Lester Crawford - resigned after 18 months in the post.
|
|
|
|
|
|
|
|
|
|
A Simple solution to the Biotechnology dilemma |
|
|
|
|
|
|
|
|
|
|
| EliseW writes "After reading up on biotechnology foods, I have to admit that all the controversy is exactly that controversial, and the only way to solve any of the problems is to meet a happy medium. The biotech corporations want to keep growing their food, backing it up saying its FDA approved and the health infused public wants to either eliminate it completely or list all genetically altered foods. Obviously both sides don’t want to give into the other. The corporations don’t want to stop making genetically altered foods for they would lose their jobs and listing genetically altered foods on the nutrition label would only scare away consumers. The public however says that the foods can be potentially detrimental to their health and it’s their right be aware if a product contains these modifications. I feel that both sides can be content by making a reference on the nutrition label that the product contains genetically altered foods and instead of listing all of the genetically altered food the corporations could just mention a website or an address where they can find more information concerning these foods. That way the consumer is aware of what they are eating and at the same time they are not scared away. "
|
|
|
|
|
|
|
|
|
|
Cracking the Cellular Code |
|
|
|
|
Posted by mlambrecht on Friday, September 10 @ 09:20:26 CEST (1626 reads)
(Read More... | 1586 bytes more | Score: 5)
|
|
|
|
|
|
| bio_informatica writes "In the past few years, biologists have churned out the entire genetic sequence of dozens of organisms, including humans, dogs, mosquitoes, rats, and bacteria. But these strings of genes amount to the most basic molecular parts list, not much more helpful to deciphering how the genes combine to run a living cell than an array of microchips and wires would be for assembling a computer. Researchers at MIT and at the MIT-affiliated Whitehead Institute for Biomedical Research have taken a major step toward understanding how those genes are organized to regulate cells."
|
|
|
|
|
|
|
|
|
|
Singapore ahead of India in biotech |
|
|
|
|
Posted by mlambrecht on Wednesday, June 30 @ 03:35:00 CEST (1584 reads)
(Read More... | 788 bytes more | Score: 0)
|
|
|
|
|
|
| "Drug company Eli Lilly's research and development (R&D) centre in Singapore has an Indian as its chief. Some of the staff and scientists at the Singapore centre are also from India. But, the operations itself are not located in India," says an Indian corporate honcho familiar with the developments. And in this statement lies a tale on the biotech race between the two countries.
|
|
|
|
|
|
|
|
|
|
Life sciences centers compared |
|
|
|
|
Posted by mlambrecht on Saturday, June 12 @ 15:10:43 CEST (1581 reads)
(Read More... | 530 bytes more | Score: 0)
|
|
|
|
|
|
| A French study comparing the excellence of research at biomedical research institutes in the United States and Europe has highlighted the symbiotic relationship between basic research and a thriving biotech industry.
|
|
|
|
|
|
|
|
|
|
Open-source in drug-discovery |
|
|
|
|
Posted by mlambrecht on Friday, June 11 @ 10:31:05 CEST (1692 reads)
(Read More... | 833 bytes more | Score: 0)
|
|
|
|
|
|
| The Economist has a nice article describing the possibilities of applying well-known open-source principles on biotech and medicine. According to the paper, it could be applied in two fields: for those drugs of which the patent has expired, and for diseases with a niche or uneconomic market (e.g. developing countries). I think it wouldn't work perfectly though.
|
|
|
|
|
|
|
|
|
|
3-D micro-imaging technology licensed to Carl Zeiss Jena by Cornell |
|
|
|
|
Posted by wvcrieki on Saturday, May 29 @ 02:34:04 CEST (1642 reads)
(Read More... | 2679 bytes more | Score: 0)
|
|
|
|
|
|
Biomedical microscopic imaging deep inside living tissue with unprecedented clarity could become routine and widely available with the signing of technology-transfer and collaborative-research agreements today (May 28, 2004) by Carl Zeiss Jena GmbH, a leading maker of microscopy instrumentation, and by CCTEC, the technology, enterprise and commercialization arm of Cornell University.
|
|
|
|
|
|
|
|
|
|
Biotech Graveyard |
|
|
|
|
|
|
|
|
|
|
| sgs writes "Can't find a company you know used to be here? Check the graveyard for companies of days long (or not so long) passed. Includes companies which have simply had a name change (280 corpses). Who makes the biotech equivalent of stiffs.com ?"
|
|
|
|
|
|
|
|
|
|
The Pace and Proliferation of Biological Technologies |
|
|
|
|
Posted by mlambrecht on Monday, March 08 @ 22:05:57 CET (1349 reads)
(Read More... | 676 bytes more | Score: 0)
|
|
|
|
|
|
| derekmatthews writes ""...The parts for a DNA synthesizer can
now be purchased for approximately
$10,000. By 2010 a single person
will be able to sequence or
synthesize 10^10 bases a day. Within
a decade a single person could
sequence or synthesize all the DNA
describing all the people on the
planet many times over in an
eight-hour day or sequence his or
her own DNA within seconds..."
"
|
|
|
|
|
|
|
|
|
|
Invitrogen Names Two Executives in Bioinformatics |
|
|
|
|
Posted by mlambrecht on Sunday, February 22 @ 08:25:00 CET (1556 reads)
(Read More... | 527 bytes more | Score: 0)
|
|
|
|
|
|
| Invitrogen Corp announced Feb 19th that it has named Michael Stapleton, Ph.D., general manager and vice president of its bioinformatics business. Additionally, the company named Vivien Bonazzi, Ph.D., director, research and development, bioinformatics. Both positions exemplify Invitrogen's commitment to making bioinformatics an integral part of its solution set for life science research.
|
|
|
|
|
|
|
|
|
|
A Danish biotech company has developed a genetically modified flower that could |
|
|
|
|
Posted by mlambrecht on Monday, February 16 @ 07:05:00 CET (1382 reads)
(Read More... | 652 bytes more | Score: 0)
|
|
|
|
|
|
| A Danish biotech company has developed a genetically modified flower that could help detect land mines and it hopes to have a prototype ready for use within a few years.
|
|
|
|
|
|
|
|
|
|
GlaxoSmithKline: Putting Genomics to Work Today |
|
|
|
|
Posted by mlambrecht on Saturday, February 14 @ 23:59:23 CET (1429 reads)
(Read More... | 581 bytes more | Score: 0)
|
|
|
|
|
|
GlaxoSmithKline (GSK) is building a secret weapon for drug development, and the company desperately needs one. When GlaxoWellcome and SmithKline Beecham joined in 2000, they created what is now the second-largest pharmaceutical company in the world.
|
|
|
|
|
|
|
|
|
|
|
Login |
|
|
|
|
| Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. |
|
|
|
|
|
|
|
|
|
Who's Online |
|
|
|
|
There are currently, 5 guest(s) and 0 member(s) that are online.
You are Anonymous user. You can register for free by clicking here |
|
|
|
|
|
|
|
|
|
Past Articles |
|
|
|
|
| _STORIESPUBLISHED 813 |
| Sunday, October 02 | | · | NIH Awards Grant to Stanford to Launch Biomedical Computation Center (603) |
| Sunday, September 18 | | · | Panel Backs One Drug but Not Second (586) |
| Wednesday, September 14 | | · | EC Funds EBI to Explore Interface Between Bioinformatics, Medical Informatics (547) |
| Monday, September 05 | | · | GM potatoes safer than organic? (562) |
| Monday, July 18 | | · | European Meeting on Drug Discovery Applications of Cheminformatics & Modelling (542) |
| · | Philadelphia Meeting: Drug Discovery Applications of Cheminformatics & Modeling (553) |
| Monday, July 04 | | · | Bioinformatics.be (530) |
| · | Biobix.be (513) |
| · | BioScope: A new bioinformatics cluster initiative (528) |
| · | Interoperability Architecture of the Cancer Biomedical Informatics Grid (520) |
| · | mpiBLAST evolves - Success, Collaborations, and Challenges (520) |
| · | The First Impact Factor for PLoS Biology—13.9 (544) |
| · | Devgen raises additional 3.7 million euros (523) |
| · | Ariadne Genomics, AAAS Agreement Helps Researchers to Manipulate Data (527) |
| Wednesday, June 22 | | · | The SeqPad software suite Released (517) |
| Monday, June 20 | | · | Justices Expand Rights to Experiment with Patented Drugs (526) |
| · | Blue Genes, Brains, IBM And A Bunch Of Teraflops (509) |
| Monday, June 06 | | · | Devgen raises € 30 million in succesful IPO (516) |
| Monday, May 16 | | · | AlgoNomics Gives Genmab Access to Bioinformatics Platform in Agreement (487) |
| Wednesday, April 27 | | · | Scientists push bacteria to quadruple hydrogen production (558) |
| · | Antibody may treat West Nile (522) |
| Tuesday, April 26 | | · | NCBI Entrez Gene : (bio)perl parser (505) |
| Thursday, April 21 | | · | LION bioscience Plans to Sell Its Bioinformatics Business (523) |
| Wednesday, April 13 | | · | Encoding non-genetic information in DNA (556) |
| Thursday, April 07 | | · | Scientists Analyze Chromosomes 2 and 4 (493) |
| Tuesday, April 05 | | · | Use of zinc-finger proteins to correct human genes (507) |
| Monday, April 04 | | · | US-India research team completes analysis of X chromosome (493) |
| Tuesday, March 22 | | · | Human Gene Master List (506) |
| · | Scientists find microRNA regulates Ras cancer gene (491) |
| · | Self-replicating 3D printer (512) |
Older Articles
|
|
|
|
|
|
|
|
